Clinical Trial Update: The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome [Phase 3]

View source ↗

Summary

This update summarizes the completed Phase 3 study evaluating the safety and efficacy of Ampligen in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome
• Myalgic Encephalomyelitis

Drugs mentioned

• Ampligen (rintatolimod)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 3 | Status: COMPLETED